Share chart Novartis AG
Extended chart
Simple chart
About Novartis AG
Novartis AG исследует, разрабатывает, производит и продает товары для здравоохранения по всему миру. Сегмент инновационных лекарств предлагает лекарства, отпускаемые по рецепту, пациентам и поставщикам медицинских услуг. Он также предлагает продукты для офтальмологии, нейробиологии, иммунологии, гепатологии и дерматологии, респираторной, кардиометаболической, традиционной медицины, а также сердечно-сосудистой, почечной и метаболической медицины. more detailsMain settings
ISIN
CH0012005267
Industry
Pharmaceuticals
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
3.39
Дивиденд ао
3.85
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 3.78 | 4 |
| P/BV | 4.43 | 4 |
| P/E | 16.38 | 7 |
Efficiency
| Title | Value | Grade |
| ROA | 11.81 | 4 |
| ROE | 26.33 | 8 |
| ROIC | 27.51 | 8 |
Dividends
| Title | Value | Grade |
| Dividend yield | 3.39 | 8.48 |
| DSI | 0.8571 | 8.57 |
| Average dividend growth | 4.37 | 7.29 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | 1.51 | 7 |
| Debt/Ratio | 0.3057 | 10 |
| Debt/Equity | 1.32 | 8 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | 3.94 | 1 |
| Yield Ebitda, % | 19.95 | 3 |
| Yield EPS, % | 66.7 | 8 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 118.38 $ | 0 $ | 0 $ | -0.32 % | 0 % | 0 % |
| Week | 117.6 $ | 118 $ | 118.38 $ | 0.34 % | 0 % | 0 % |
| Month | 109.8 $ | 106.5 $ | 118.38 $ | 7.47 % | 0 % | 0 % |
| Three month | 98.25 $ | 98.25 $ | 118.38 $ | 20.1 % | 0 % | 0 % |
| Half a year | 104.75 $ | 94.7 $ | 119.85 $ | 12.65 % | 0 % | 0 % |
| Year | 115.5 $ | 94.7 $ | 122.49 $ | 2.16 % | 0 % | 0 % |
| 3 years | 76.4 $ | 73 $ | 122.49 $ | 54.45 % | 0 % | 0 % |
| 5 years | 87.89 $ | 73 $ | 122.49 $ | 34.25 % | 0 % | 0 % |
| 10 years | 0 $ | 59.2 $ | 122.49 $ | 0 % | 0 % | 0 % |
| Year to date | 107.92 $ | 96.32 $ | 119.85 $ | 9.34 % | 0 % | 0 % |
Main owners
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Mr. Harry Kirsch | Chief Financial Officer | 4.02M | 1965 (60 years) |
| Dr. Klaus Moosmayer Ph.D. | Chief Ethics, Risk & Compliance Officer | 1.56M | 1968 (57 years) |
| Ms. Karen L. Hale | Chief Legal Officer | 2.36M | 1968 (57 years) |
| Dr. Robert Kowalski Pharm.D. | Chief People & Organization Officer | 2.12M | 1968 (57 years) |
| Dr. Steffen Lang Ph.D. | President of Operations | 2.35M | 1967 (58 years) |
| Mr. Victor Bulto | President of US | 3.3M | 1978 (47 years) |
| Dr. Vasant Narasimhan M.D. | Chief Executive Officer | 8.07M | 1976 (49 years) |
| Dr. Patrick Horber M.D. | President of International | 7.36M | 1970 (55 years) |
| Paul Penepent | Head of Group Financial Reporting and Accounting | N/A | |
| Ms. Sloan Simpson | Global Head of Investor Relations |
About company
Address: Switzerland, Basel, Lichtstrasse 35 - Open in google maps, Open in yandex maps
Website: http://www.novartis.com
Website: http://www.novartis.com
